



# BISOPROLOL Solution

Designed for patients  
with swallowing difficulties  
or those who require  
administration via  
a nasogastric tube

## ● Indications for Use:

### **Chronic Heart Failure (CHF) with Reduced Systolic Left Ventricular Function:**

- Bisoprolol is indicated for the treatment of stable chronic heart failure in patients with reduced systolic left ventricular function.
- It complements existing therapies such as ACE inhibitors, diuretics, and optionally cardiac glycosides.

### **Hypertension (High Blood Pressure):**

- Additionally, it is effective in the treatment of hypertension (high blood pressure).

### **Angina (Chest Pain):**

- It is also used for the management of angina, providing relief from chest pain associated with reduced blood flow to the heart.

Ready-to-use solution  
for adult use

Allows for convenient  
dosing using an oral  
syringe

Available strength: 2.5mg/5 ml  
(dosage in the range of 1.25 - 10mg can be administered)

## **Benefit for the Target Population:**

- The product containing Bisoprolol in the form of an oral liquid (solution) is specifically intended for patients with swallowing difficulties.
- It serves as a substitute for tablets, enhancing patient compliance.
- Additionally, it helps lower the pill burden for patients.

## **Reference Markets:**

- Bisoprolol remains the largest beta-blocker, with approximately 2.0 billion tablets sold (MAT Q2 2022) according to IQVIA data for the EU27+UK.



### Regulatory pathway

- Legal basis: Article 10(3) hybrid application

### Development status

- Our clinical strategy includes assessing the bioequivalence of the solution vs. tablets, which has been confirmed through a successful bioequivalence study.
- The dossier submission is planned for May 2024.

### Partnership options

- The product is available for out-licensing in select European markets
- The product is also available for licensing outside of Europe

**DISCLAIMER:** Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.